Abstract
A number of urea derivatives were synthesized and screened for their urease and α-chymotrypsin inhibition effects, whereby one of the compounds, N-4-nitrophenyl-N’-4’-nitrophenylurea (3), showed strong urease inhibition (IC50 = 1.25μM). We found that the same compound is also an efficient α-chymotrypsin inhibitor having an IC50 value of 3.15μM.
Keywords: Urease, α-chymotrypsin, Urea derivatives
Letters in Drug Design & Discovery
Title: Urease and α-Chymotrypsin Inhibitory Effects of Selected Urea Derivatives
Volume: 5 Issue: 6
Author(s): Shahnaz Perveen, Khalid Mohammed Khan, Muhammad Arif Lodhi, Muhammad Iqbal Choudhary, Atta-ur-Rahman and Wolfgang Voelter
Affiliation:
Keywords: Urease, α-chymotrypsin, Urea derivatives
Abstract: A number of urea derivatives were synthesized and screened for their urease and α-chymotrypsin inhibition effects, whereby one of the compounds, N-4-nitrophenyl-N’-4’-nitrophenylurea (3), showed strong urease inhibition (IC50 = 1.25μM). We found that the same compound is also an efficient α-chymotrypsin inhibitor having an IC50 value of 3.15μM.
Export Options
About this article
Cite this article as:
Perveen Shahnaz, Khan Mohammed Khalid, Lodhi Arif Muhammad, Choudhary Iqbal Muhammad, Atta-ur-Rahman and Voelter Wolfgang, Urease and α-Chymotrypsin Inhibitory Effects of Selected Urea Derivatives, Letters in Drug Design & Discovery 2008; 5 (6) . https://dx.doi.org/10.2174/157018008785777315
DOI https://dx.doi.org/10.2174/157018008785777315 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Application and Interpretation of Genome-Wide Association (GWA) Studies for Informing Pharmacogenomic Research - Examples from the Field of Age-Related Macular Degeneration
Current Molecular Medicine Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Current Pharmaceutical Design Proresolution Mediators and Receptors: Novel Drug Targets for Enhancing Pharmacological Armamentarium against Periodontal Inflammation
Infectious Disorders - Drug Targets The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Strategies for the Design of Potent and Selective Kinase Inhibitors
Current Pharmaceutical Design Elevated Expression of A-Raf and FA2H in Hepatocellular Carcinoma is Associated with Lipid Metabolism Dysregulation and Cancer Progression
Anti-Cancer Agents in Medicinal Chemistry Molecular Kinetics and Targeting Within the Nucleus
Current Chemical Biology Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry FLT3 Inhibition in Acute Myeloid Leukaemia – Current Knowledge and Future Prospects
Current Cancer Drug Targets Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery VEGF Promotes Glycolysis in Pancreatic Cancer via HIF1α Up-Regulation
Current Molecular Medicine Part I: Targeted Particles for Cancer Immunotherapy
Current Drug Delivery